

# ForPatients

by Roche

## Obesity

### A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

**Trial Status**  
Recruiting

**Trial Runs In**  
1 Country

**Trial Identifier**  
NCT07670416 YC46401

---

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

#### **Official Title:**

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus

#### **Trial Summary:**

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT07670416 YC46401**  
Trial Identifiers

---

#### **Eligibility Criteria:**

**Gender**  
All

**Age**  
#18 Years

**Healthy Volunteers**  
No

---

#### **Inclusion Criteria:**

- Body mass index (BMI) #24.0 kilograms per meter squared (kg/m<sup>2</sup>) for participants with type 2 diabetes mellitus (T2DM)

# ForPatients

*by Roche*

- BMI  $\geq 28.0$  kg/m<sup>2</sup> or BMI  $\geq 24.0$  and  $< 28.0$  kg/m<sup>2</sup> and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, or weight-related cardiovascular disease) for participants without T2DM
- Agreement to adhere to the contraception requirements

## ***Exclusion Criteria:***

- History of Type 1 diabetes mellitus (T1DM)
- Obesity induced by other endocrinologic disorders
- Any planned major medical procedure or surgery during the study
- History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder
- Any lifetime history of suicide attempt
- History of any hematologic conditions that may interfere with HbA1c measurement
- History of acute or chronic pancreatitis or clinically significant gallbladder disease
- Treatment with any approved or investigational GLP-1-RA-based therapy within 6 months prior to randomization
- Treatment with other investigational therapy within 3 months prior to randomization or less than 5 elimination half-lives prior to randomization, whichever is longer
- Known allergy to any component of the study drug formulation or any other condition that is a contraindication to GLP-1 RAs or GLP-1/GIP RAs